Program
DDY391
A development code.
In Novartis's pipeline, VAV1-directed MGD
. Its studies are mostly in Arthritis, Psoriatic · Sjogren's Syndrome, led by Novartis.
Furthest: phase 2, since Jul 27, 20263 company-led studies, 3 open or runningNext primary completion: Dec 13, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 33 open or running | phase 2since Jul 27, 2026 | Jul 27, 2026 | Dec 13, 2028phase 2 · NCT07801495 |
- Named in Novartis’s own pipeline as
DDY391
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 27, 2026First study: phase 2 study in Sjogren's SyndromeFirst studyNCT07737743 · 344 planned · United States, Australia, Canada and more
- Aug 31, 2026Phase 2 study in Arthritis, PsoriaticNCT07801495 · 220 planned · United States
- Nov 2, 2026Phase 2 study in Arthritis, PsoriaticNCT07923773 · 88 planned
Ahead
- Dec 13, 2028Primary completion: phase 2 study in Arthritis, PsoriaticNCT07801495
- Feb 19, 2029Primary completion: phase 2 study in Sjogren's SyndromeNCT07737743
- Dec 12, 2029Primary completion: phase 2 study in Arthritis, PsoriaticNCT07923773
TargetBeta
“VAV1-directed MGD”the company's pipeline, read by Claude · source
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07923773Arthritis, Psoriatic | 2 | Not yet recruiting | Dec 12, 2029 | 88 |
| NCT07801495Arthritis, Psoriatic · United States | 2 | Recruiting | Dec 13, 2028 | 220 |
| NCT07737743Sjogren's Syndrome · United States, Australia, Canada and more | 2 | Recruiting | Feb 19, 2029 | 344 |
How it is read
Names in the registry
- “DDY391”, 3 entries
Codes read as this program: DDY391.
Conditions, from the studies’ own filings
- Arthritis, Psoriatic, 2 studies
- Sjogren's Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.